Inventiva S.A. (IVA) — research page

US · us-cm-kg/NASDAQ/IVA · as of 2026-11-08

Identity and listing

The issuer is Inventiva S.A., listed on NASDAQ under ticker IVA. Its ISIN is US46124U1079. Its LEI is not on the record, as there is no GLEIF record with the exact legal name in jurisdiction US-I0. Its security type is non-operating entity type (other), its segment is not on the record, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is France. The issuer is listed and not halted.

The disclosure read

The record holds 43 filings in the twelve months to 2026-11-08, across 30 filing days: 4 prospectus, 16 regulatory filing and 23 results. The median gap between filing days is 6 days. The latest filing is dated 2026-10-27 and is a regulatory filing, 12 days before the record date. The exchange median on NASDAQ is 6.0 days cadence, 52 filings and 5.0 days latency across 4,359 issuers. The sector median for 2834 Pharmaceutical Preparations is 6.0 days cadence, 63.0 filings and 4.0 days latency across 526 issuers.

window 2025-11-08 to 2026-11-08 · the node's disclosure lines, as get_filings serves them

Auditor

The auditor is not on the record, as there is no dei:AuditorName tag on the latest annual report cover, and foreign private issuers and older filings carry none. The auditor location is not on the record. The record holds no auditor changes.

Events and halts

The record holds no listing, delisting or name change lines. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.

Orderability

The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.

rule acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability

Coverage

The record finds 17 research houses named on the issuer's own investor-relations page: Barclays, Canaccord Genuity, Cantor Fitzgerald, Guggenheim, HC Wainwright, Jefferies, KBC, Leerink, LifeSci Capital, Piper Sandler, Portzamparc BNP Paribas, Stifel, TD Cowen, Truist, UBS, Van Lanschot Kempen and Wolfe Research.

Open research

The record holds no openly published research notes on the issuer. None was found.

Licensed

Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.

As-of depth

The record holds sealed years 2021, 2022, 2023, 2024, 2025 and 2026 for the issuer. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.

Sources

8 source pages are named on this page; every value above carries its own source page and read date in the numbers.

10.1

https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)

10.2

https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)

10.3

https://data.sec.gov/submissions/CIK0001756594.json (identity.jurisdiction)

10.4

https://mcp.us-cm-kg.ai/events/NASDAQ/IVA (the disclosure lines)

10.5

https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)

10.6

https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)

10.7

https://inventivapharma.com/investors/stocks/ (coverage)

10.8

https://mcp.us-cm-kg.ai/record/NASDAQ/IVA (the record)

Read it by agent

The same page, signed and receipted: get_research at https://mcp.getissuer.ai/mcp with {"isin":"US46124U1079"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:9871125929b2dcf2.